Synthesis and evaluation of 13N-labelled azo compounds for β-amyloid imaging in mice

Molecular Imaging and Biology

Volumn 16, Issue 4, 2014, Pages 538-549

  Gaja, Vijay ^a   Gómez Vallejo, Vanessa ^a   Puigivila, Maria ^a   Pérez Campaña, Carlos ^a   Martin, Abraham ^a   García Osta, Ana ^b   Calvo Fernández, Teresa ^a   Cuadrado Tejedor, Mar ^b   Franco, Rafael ^b,c   Llop, Jordi ^a  

^a CIC BIOMAGUNE   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer's disease; Animal biomarker; Nitrogen 13; Positron emission tomography; Tg2576; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AZO COMPOUND; RADIOPHARMACEUTICAL AGENT; LIGAND; NITROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING ASSAY; BLOOD BRAIN BARRIER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMISTRY; HIPPOCAMPUS; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ANIMALIA; MUS;

AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; AZO COMPOUNDS; HIPPOCAMPUS; LIGANDS; MICE, INBRED C57BL; MICE, TRANSGENIC; NITROGEN ISOTOPES; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84904431330     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0708-x     Document Type: Article

References (31)

1. Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337:1488-1492
2. Sajid J, Elhaddaoui A, Turrell S (1997) Investigation of the binding of Congo red to amyloid in Alzheimer's diseased tissue. J Mol Struct 408-409:181-184 (Pubitemid 27402915)
3. Hardy JA, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: problems and progress on the road to therapeutics. Science 297:353-356
4. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319 (Pubitemid 38269583)
5. 18F- flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319-329
6. 18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis 10:246-249
7. 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 53:415-424
8. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129-135
9. 18-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51:913-920
10. Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med 42:423-432
11. Kepe V, Moghbel MC, Långström B et al (2013) Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis. doi:10.3233/JAD-130485
12. Montine TJ, Phelps CH, Beach TG et al (2012) National Institute on Aging-Alzheimer 's Association guidelines for the neuropathologic assessment of Alzheimer' s disease: a practical approach. Acta Neuropathol 123:1-11
13. Hyman BT, Phelps CH, Beach TG et al (2012) Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8:1-13
14. Agdeppa ED, Kepe V, Liu J et al (2001) Binding characteristics of radio fluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 21:RC189
15. 18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol 11:236-240
16. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600
17. Klunk WE, Lopresti BJ, Ikonomovic MD et al (2005) Binding of the positron emission tomography tracer Pittsburgh Compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25:10598-10606 (Pubitemid 41681907)
18. Higuchi M, Maeda J, Ji B et al (2010) In vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: insights from neuroimaging research in humans and rodent models. Biochim Biophys Acta 1802:373-388
19. Maeda J, Ji B, Irie T et al (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27:10957-10968 (Pubitemid 47574168)
20. 18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging 33:2561-2571
21. 13N-labelled azo compounds: a new route for the preparation of amyloid imaging PET probes. Eur J Med Chem 45:5318-5323
22. 13N-labelled radiotracers by using microfluidic technology. J Labelled Comp Radiopharm 55:332-338
23. Logan J, Fowler JS, Volkow ND et al (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834-840 (Pubitemid 26292051)
24. Reilly JF, Games D, Rydel RE et al (2003) Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A 100:4837-4842 (Pubitemid 36457815)
25. Dickson DW, Farlo J, Davies P et al (1988) Alzheimer's disease. A double-labelling immunohistochemical study of senile plaques. Am J Pathol 132:86-101
26. Villemagne VL, Klunk WE, Mathis CA et al (2012) Aβ imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 39:209-219
27. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134:1089-1100
28. Zhang W, Arteaga J, Cashion DK et al (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31:601-602
29. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement, in press, Corrected Proof, doi: 10.1016/j.jalz.2012.11.008
30. 11C]PIB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS ONE 7(3):e31310
31. Dishino DD, Welch MJ, Kilbourn MR, Raichle ME (1983) Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 24:1030-1038 (Pubitemid 14206457)